

STATE OF CONNECTICUT

DEPARTMENT OF PUBLIC HEALTH

Renée D. Coleman-Mitchell, MPH
Commissioner



Ned Lamont
Governor
Susan Bysiewicz
Lt. Governor

HEALTHCARE QUALITY AND SAFETY BRANCH

BLAST FAX 2019-10

TO: Nursing Home Administrators

FROM: Barbara Cass, R.N., Branch Chief *BSU*
Healthcare Quality and Safety Branch

DATE: July 8, 2019

SUBJECT: Medication Assisted Treatment in Nursing Homes, Buprenorphine Waiver Training

Please see the attached training opportunity. For more information or to register, please visit:

www.womensconsortium.org



Telecommunications Relay Service 7-1-1
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
www.ct.gov/dph

Affirmative Action/Equal Opportunity Employer





The Connecticut Women's Consortium

Medication Assisted Treatment: MAT 8-Hour Waiver Training

July 25th, 2019

This training is designed for healthcare professionals treating individuals with opioid use disorders. This training is required for physicians to be able to apply for the waiver from the Drug Enforcement Agency to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Nurse Practitioners and Physician assistants are required to complete 24 hours of training including this 8-hour MAT training.

American Academy of Addiction Psychiatry (AAAP) is the DATA 2000 sponsor for this training. Funding for this conference was made possible (in part) by (6H79T1026749-03M001) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.



Providers
Clinical Support
System



For more information or to register at www.womeniscoalition.org

Charles Atkins, MD, Craig Allen, MD & Lori Sobel, MD

2321 Whitney Avenue, Suite 401, Hamden, CT 06518 | 2nd Floor



8am-5pm | \$30



CME Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Addiction Psychiatry and the Connecticut Women's Consortium. AAAP is accredited by the ACCME to provide continuing medical education for physicians.

Credit designation: American Academy of Addiction Psychiatry (AAAP) designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of physician participation in the learning process: Credit will only be awarded for completing all of the training. To be awarded a maximum of 8 AMA PRA Category 1 Credits™ and a Buprenorphine Training Completion Certificate you must complete all 8 hours of the course. Those completing the course will be able to complete the waiver application online.

At the conclusion of this activity, participants should be able to:

- Review addiction identification and evidence-based treatments.
- Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
- Discuss other approved antagonist and agonist medications to treat OUD.
- Discuss basic office protocols including medical record documentation and confidentiality.
- Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
- Apply for a MAT Waiver Training Certificate to begin treating patients with OUD.